Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides (NYSE American: NNVC) CEO Dr Anil Diwan told Proactive (Oct 29, 2025) that lead drug NV-387 showed potent anti-measles activity in cell culture and a humanized animal model and protected lung tissue.
In a lethal measles model, NV-387 extended survival by 130% (from 7.4 days to 17 days). NV-387 completed Phase I with no reportable adverse events and is formulated as oral gummies. The company said it can support emergency use or physician-initiated INDs and is advancing NV-387 into Phase II for MPox.
NanoViricides (NYSE American: NNVC) CEO Dr Anil Diwan della NanoViricides (NYSE American: NNVC) ha detto a Proactive (29 ottobre 2025) che il lead drug NV-387 ha mostrato una potente attività antir-morbillo in coltura cellulare e in un modello animale umanizzato, e ha protetto i tessuti polmonari.
In un modello letale di morbillo, NV-387 ha esteso la sopravvivenza del 130% (da 7,4 giorni a 17 giorni). NV-387 ha completato la Fase I senza nessun evento avverso rilevabile ed è formulato come gomme orali. L’azienda ha dichiarato che può supportare l’uso di emergenza o IND avviati dai medici e sta portando NV-387 alla Fase II per MPox.
El CEO Dr Anil Diwan de NanoViricides (NYSE American: NNVC) dijo a Proactive (29 de octubre de 2025) que el fármaco principal NV-387 mostró una potente actividad anti‐sarampión en cultivo celular y en un modelo animal humanizado, y protegió el tejido pulmonar.
En un modelo letal de sarampión, NV-387 prolongó la supervivencia en 130% (de 7,4 días a 17 días). NV-387 completó la Fase I sin eventos adversos reportables y está formulado como gomitas orales. La compañía dijo que puede apoyar uso de emergencia o IND iniciados por médicos y está llevando NV-387 a la Fase II para MPox.
나노버시드(NYSE American: NNVC)의 CEO Anil Diwan 박사는 Proactive(2025년 10월 29일)과의 인터뷰에서 주도 약물 NV-387이 세포 배양 및 인간화된 동물 모델에서 강력한 홍역에 대한 활성을 보였고 폐 조직을 보호했다고 말했다.
치명적인 홍역 모델에서 NV-387은 생존 기간을 130% 증가시켰으며(7.4일에서 17일로), NV-387은 1상에서 보고 가능한 이상 반응이 없음을 보였고 구강 젤리 형태로 제형되어 있다. 회사는 긴급 사용 또는 의사가 시작한 IND를 지원할 수 있으며 NV-387을 MPox의 2상으로 진행 중이라고 밝혔다.
Le PDG de NanoViricides (NYSE American: NNVC) Dr Anil Diwan a déclaré à Proactive (29 octobre 2025) que le candidat principal NV-387 a montré une activité puissante contre la rougeole en culture cellulaire et dans un modèle animal humanisé, et a protégé les tissus pulmonaires.
Dans un modèle mortel de rougeole, NV-387 a prolongé la survie de 130% (de 7,4 jours à 17 jours). NV-387 a terminé la phase I sans événements indésirables rapportables et est formulé sous forme de gommes orales. La société a déclaré qu’elle peut soutenir l’usage d’urgence ou les IND initiés par les médecins et fait progresser NV-387 vers la phase II pour MPox.
NanoViricides (NYSE American: NNVC) CEO Dr. Anil Diwan sagte gegenüber Proactive (29. Okt. 2025), dass der leitende Wirkstoff NV-387 in Zellkultur und in einem humanisierten Tiermodell eine potente Aktivität gegen Masern zeigte und Lungengewebe schützte.
In einem tödlichen Masernmodell verlängerte NV-387 das Überleben um 130% (von 7,4 Tagen auf 17 Tage). NV-387 hat Phase I mit keine berichtbaren Nebenwirkungen abgeschlossen und ist als orale Gummis formuliert. Das Unternehmen sagte, es könne Notfallgebrauch oder von Ärzten initiierte INDs unterstützen und NV-387 in Phase II für MPox vorantreiben.
صرّح الدكتور أنيل ديوان، الرئيس التنفيذي لشركة NanoViricides (بورصة NYSE American: NNVC)، لشركة Proactive في 29 أكتوبر 2025 بأن الدواء القيادي NV-387 أظهر نشاطاً قوياً مضاداً للحصبة في زراعة الخلايا ونموذج حيواني مُحوّر، وحماية أنسجة الرئة.
في نموذج حصبة خطير، زاد NV-387 فترة البقاء على قيد الحياة بنسبة 130% (من 7.4 أيام إلى 17 يومًا). أكمل NV-387 المرحلة I بدون أحداث جانبية قابلة للإبلاغ وهو مُكوّن على شكل حلوى فموية. قالت الشركة إنها يمكن أن تدعم الاستخدام في حالات الطوارئ أو INDs التي يبدأها الأطباء وتواصل تقدم NV-387 إلى المرحلة II من MPox.
NanoViricides (NYSE American: NNVC) 首席执行官 Anil Diwan 博士告诉 Proactive（2025年10月29日）主导药物 NV-387 在细胞培养和人源化动物模型中显示出对麻疹的强效活性，并保护了肺组织。
在一个致命性麻疹模型中，NV-387 将生存期延长了 130%（从 7.4 天增至 17 天）。NV-387 已完成 I 期，无可报告的不良事件，并以口服软糖形式制剂。公司表示可以支持紧急使用或由医生启动的 IND，并正在推进 NV-387 进入 MPox 的 II 期。
- Survival extended 130% (7.4 days to 17 days) in animal model
- Demonstrated activity in cell culture and humanized animal model
- Phase I completed with no reportable adverse events
- Oral gummy formulation that dissolves in mouth (patient-friendly)
- Advancing NV-387 into Phase II for MPox
- Company states no assurance that preclinical results will lead to clinical success
- Company cannot project an IND filing date due to external collaborator dependencies
Insights
NV-387 shows compelling preclinical efficacy and Phase I safety; potential clinical pathway exists but remains early-stage.
NanoViricides reported that NV-387 produced direct antiviral activity in cell culture and extended survival in a humanized, immunodeficient measles mouse model from 7.4 to 17 days, a
The program has completed Phase I human testing with no reportable adverse events, and the company stated readiness to support emergency use pathways and physician-initiated INDs. These facts show a clear translational path but do not prove clinical benefit in patients.
Watch for a formal IND filing, receipt of regulatory feedback, and any human efficacy signals in controlled trials over the next 6–24 months from
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share major progress in the company's antiviral research in a video interview. The interview can be viewed at https://youtu.be/m_3Yk4_832E .
From the Proactive website, explaining the video content (https://www.proactiveinvestors.com/companies/news/1081157/nanoviricides-nv-387-shows-potent-anti-measles-activity-highlighting-broad-spectrum-potential.html):
"Dr. Diwan shared that the Company's clinical lead drug NV-387 has demonstrated potent activity against the Measles virus in both cell culture studies and a humanized animal model. Notably, the treatment also protected lung tissue, a critical factor in preventing death from severe, late-stage viral infections. Currently, there are no approved drugs for treating Measles, making these findings especially significant amid rising global outbreaks.
Dr. Diwan explained that NV-387 produced direct antiviral effects in standard Cytopathic Effects assays, where treated cells showed increased survival compared to untreated controls. In the lethal Measles infection model, NV-387 treatment extended survival by
Importantly, NV-387 has already completed Phase I human trials, demonstrating no reportable adverse events and confirming that the drug is safe and well tolerated in healthy subjects.
Dr. Diwan added that NanoViricides is now positioned to support emergency use applications of NV-387 for Measles patients under FDA guidelines. The company is also open to Physician's Investigator-Initiated INDs for treating individual or small groups of patients in urgent cases. NV-387 is formulated as oral gummies, which dissolve slowly in the mouth and do not require swallowing - a key advantage for patients suffering from rashes or throat irritation associated with Measles infection.
The same drug, NV-387 is advancing into Phase II clinical trial for the evaluation of safety and effectiveness in the treatment of MPox, noted Dr. Diwan. There is no approved treatment for MPox. "
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
[1] Added explanation: Humanized mice were required for the animal model because Measles virus only infects humans, and specifically uses hSLAM as the cognate receptor for cell entry, while using the ubiquitous HSPG for congregation next to cells. The mice had human hSLAM (aka hCD150) gene knocked-in, and also had their interferon responses deleted (hSLAM+k.i., IfnAR-/- transgenic mice on C57BL/6 Background). NV-387 mimics the portions on HSPG that viruses bind to, including the Measles virus, and thereby is designed to attack and engulf the virus particle via lipid-lipid mixing and destroying the virus particle's ability to infect cells.
SOURCE: NanoViricides
View the original press release on ACCESS Newswire
FAQ
What did NanoViricides announce about NV-387 on October 29, 2025 (NNVC)?
Has NV-387 completed human trials and is it safe (NNVC)?
Can NV-387 be used now for measles patients under FDA rules (NNVC)?
What is the formulation advantage of NV-387 mentioned by NanoViricides (NNVC)?
Is NanoViricides advancing NV-387 for other diseases (NNVC)?
What investor risks did NanoViricides highlight about NV-387 (NNVC)?
